Cullinan Therapeutics (CGEM) Accounts Payables (2020 - 2026)

Cullinan Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 26.23% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (down 26.23% YoY), while the FY2025 annual figure was $841000.0, down 50.0% from the prior year.
• Accounts Payables for Q1 2026 stood at $2.5 million, up from $841000.0 in the prior quarter.
• The five-year high for Accounts Payables was $6.3 million in Q1 2022, with the low at $841000.0 in Q4 2025.
• The 5-year median for Accounts Payables is $2.5 million (2025), against an average of $2.4 million.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables plunged 67.79% in 2023, then surged 122.4% in 2024.
• Cullinan Therapeutics' Accounts Payables stood at $2.7 million in 2022, then slipped by 6.28% to $2.5 million in 2023, then plunged by 32.53% to $1.7 million in 2024, then slumped by 50.0% to $841000.0 in 2025, then jumped by 198.34% to $2.5 million in 2026.
• Business Quant data shows CGEM's Accounts Payables at $2.5 million in Q1 2026, $841000.0 in Q4 2025, and $1.7 million in Q3 2025.